<DOC>
	<DOC>NCT02542787</DOC>
	<brief_summary>Phase II a Proof of concept study in Multiple Sclerosis (MS) patients with spasticity.</brief_summary>
	<brief_title>Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis</brief_title>
	<detailed_description>Single dose escalation followed by multiple fixed dose administrations to assess short term safety and to determine whether spasticity improves.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>3-(5-dimethylcarbamoylpent-1-enyl)-N-(2-hydroxy-1-methylethyl)benzamide</mesh_term>
	<criteria>Have a confirmed diagnosis of MS Have an Expanded Disability Status Scale (EDSS) â‰¤ than 6.5 at screening. Spasticity due to MS of at least 3 months duration with minimum mean score of &gt;/=2 mASH Acute MS relapse requiring treatment with steroids within 30 days of screening. Initiation or discontinuation of MS disease modifying treatment (DMT) within 30 days of screening. Receiving medications that would potentially interfere with the actions of the study medication or outcome variables Significant renal and hepatic abnormalities Previous history of other significant medical disorders</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>MS</keyword>
	<keyword>Spasticity</keyword>
	<keyword>VSN16R</keyword>
</DOC>